Autolus Therapeutics

Autolus Therapeutics

Autolus is a biopharmaceutical company focused on programmed T-cell therapies for treatment of cancer. Autolus was founded in 2014 and is based in London, UK. Autolus Limited is a subsidiary of Autolus Holdings (UK) Limited.

Autolus develops and commercializes engineered T-cell immunotherapy products to treat cancer. Autolus supplies engineering chimeric antigen receptors (CAR) T-cell products that kill malignant cells and protect from malignancy in the long-term. The company provides T-cell products for hematological and solid tumors.

T-cells normally detect and eliminate abnormal or cancerous cells in the body but sometimes cells escape detection and develop into tumors. Autolus programs T-cells to recognize and destroy tumour cells by transferring a gene into T-cells so they express Chimeric Antigen Receptors (CARs) or T-cell receptors (TCRs) that recognize targets on the surface of malignant cells. For their process Autolus uses their own proprietary viral vector and semi-automated cell manufacturing processes. The company has a collaboration partnership with AbCellera Biologics Inc. for a project in antibody discovery.

Pipeline and products

Autolus is developing AUTO1, a programmed T cell therapy targeting CD19 to treat acute lymphoblastic B cell leukemia (ALL). The therapy designed to reduce the risk of severe cytokine release syndrome, is in a Phase I clinical trial as of 2019. Cytokine release syndrome is a condition that can occur after immunotherapy threatment and that can be life threatening. The therapy can cause immune cells to release a large release of cytokines into the blood and lead to symptoms like fever, nausea, headache, rask, rapid hearbeat, low blood pressure and trouble breathing. AUTO1 uses a novel CD19 binder that allows rapid disengagement of CAR T cells after target cell encounter and kill.

Pre-clinical and clinical data from an ongoing Phase I CARPALL trial of AUTO1 were published in Nature Medicine in 2019. In the Phase I clinical trial 86% of the pediatric ALL patients (n=14) showed molecular complete remission after a single dose with a median duration of remission of 7.4 months and no severe cytokine release syndrome.

AUTO2 is a programmed T cell therapy with two targets, for the treatment of relapsed or refractory multiple myeloma. AUTO2 is in PhaseI/II clinical trials as of 2019.

AUTO3 is a dual-targeting programmed T cell therapy for treating relapsed or refractory diffuse large B-cell lymphoma, which is in Phase I/II clinical trials as of 2019.

AUTO4 is a programmed T cell therapy for treatment of peripheral T-cell lymphoma and is in Phase I/II clinical trials as of 2019.

AUTO6 is a programmed T cell therapy for treatment of neuroblastoma.

Timeline

September 2, 2019

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

Nature Medicine (2019)

Authors from Autolus and various cancer research institutes in London, UK presented pre-clinical and clinical data on the programmed T cell therapy called AUTO1.

September 2017

Autolus Therapeutics raises a $80,000,000 series C round from Syncona Investment Management, Nextech Invest, Cormorant Asset Management, Arix Bioscience plc and Woodford Investment Management.

2014

Autolus Therapeutics was founded.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Dr. Christian Martin Itin

Chairman, CEO

Dr. Jim Faulkner, PhD

Head of Manufacturing

Dr. Louise Holliday

Head of Intellectual Property

Dr. Martin Pulé

Founder, CSO

Mr. Christopher Vann

COO

Further reading

Title
Author
Link
Type
Date

Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)

Autolus Therapeutics plc

Web

Biotech to create 170 jobs, invest $28M in new Rockville HQ

Katie Arcieri

Web

New CAR T-cell therapy for leukemia associated with fewer harmful side effects

Henry Killworth

Web

September 4, 2019

Documentaries, videos and podcasts

Title
Date
Link

Cell Therapy Commercialization in Oncology

January 8, 2019

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.